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Abstract: Published research on fucoidans increased three fold between 2000 and 2010. 
These algal derived marine carbohydrate polymers present numerous valuable bioactivities. 
This review discusses the role for fucoidan in the control of acute and chronic 
inflammation via selectin blockade, enzyme inhibition and inhibiting the complement 
cascade. The recent data on toxicology and uptake of fucoidan is detailed together with a 
discussion on the comparative activities of fractions of fucoidan from different sources. 
Recent in vivo, in vitro and clinical research related to diverse clinical needs is discussed. 
Targets include osteoarthritis, kidney and liver disease, neglected infectious diseases, 
hemopoietic stem cell modulation, protection from radiation damage and treatments for 
snake envenomation. In recent years, the production of well characterized reproducible 
fucoidan fractions on a commercial scale has become possible making therapies from 
fucoidan a realizable goal.  
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1. Introduction  
Fucoidans are a class of sulfated, fucose-rich polymers found in brown macroalgae [1,2]. They were 
identified in the first half of the last century by Kylin [3]. Subsequent research by researchers such as 
Bird [4] and Pervical [5] confirmed the basic identity of this class of compounds. Black reports the 
systematic isolation of fucoidan from a number of different British seaweeds [6]. Fucoidan was 
recognized as having a role in the biology of the seaweed, and examined over the next few decades for 
its activity in a number of biological systems. Current research interest in fucoidan is global. Research 
occurs in Australia, Japan, Korea, Russia and China in addition to Europe and the Americas. The 
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intensity of biological activities of fucoidan varies with species, molecular weight, composition, 
structure and the route of administration.  
Despite notable bioactivities and a lack of oral toxicity, fucoidans remain relatively unexploited as a 
source of therapeutics due to their plant source and heterogeneity. In recent decades pharmaceutical 
companies have preferred “druggable” well defined smaller molecules, leading to a neglect of the 
opportunities for larger and polydisperse entities. Older naturally occurring polymeric drugs such as 
heparin have held their place in the modern pharmacopeia despite recent concerns [7]. Carefully 
controlled sources of seaweed together with modern extraction and characterization methods to create 
reproducibly defined products together with new regulatory avenues mean that fucoidan fractions can 
be produced to standards suitable as ingredients in medical devices and even cross the threshold   
into drug development route [8]. There are also further potential applications for fucoidan products in 
complementary medicine and topical applications. 
The reading of the literature can be confusing due to the diverse sources and fractions of fucoidan 
used. In general, fucoidans contain a high proportion of fucose in the sugar backbone of the polymer. 
They are sulfated, may be acetylated and may also contain uronic acids. The yield of a crude first 
fraction of fucoidan is generally 2–10% by weight, although Cladosiphon species may yield over 20% 
by dry weight. Fucoidans derived from seaweeds are all highly branched. A second source of linear 
rather than branched fucoidans is echinoderms, in particular sea cucumbers, which are largely outside 
of the scope of this review. Earlier reviews on the structure and significance of the fucoidans can be 
found in Fitton [9], Pomin [10] and Berteau [2] and also by Li [11].  
The most common source of experimental fucoidan used in the literature is derived from 
Fucus vesiculosis, a common harvest crop of a northern hemisphere kelp. This fucoidan, like all 
primary fucoidan extracts, is heterodisperse and well characterized in an elegant paper by Nishino [12]. 
Fucus vesiculosis fucoidan is a high fucose sulfated fucoidan. Other common fucoidans are sourced 
from edible species such as Cladosiphon okamuranus, Laminaria japonica and Undaria pinnatifida. 
These seaweeds are harvested in significant quantities across Asia and have an excellent toxicity 
profile. The backbone sugars are different again. Undaria pinnatifida fucoidan contains a high 
proportion of galactose for example.  
This review begins by identifying new research in uptake and toxicity of fucoidans. Secondly, this 
review limits the scope of potential therapeutic use of fucoidan in inflammation related areas; injury, 
infection, chronic inflammation and fibrosis, and lastly, protection of neuronal function. These areas 
represent areas of need for new approaches and perhaps greater potential for commercialization of new 
technology. It is not inferred that other areas of fucoidan bioactivity are not important, or indeed, any 
less likely to lead to real world therapeutic use. Research into the cancer inhibitory effects of fucoidan 
fractions is reviewed elsewhere [2,9] and not within the scope of this review. 
2. Uptake and Fate of Fucoidan 
The yet unanswered question is “Where does fucoidan go after oral, intraperitoneal or intravenous 
administration?” Although a number of research papers indicate biological effects after oral ingestion 
or systemic delivery, very little research has taken place on the uptake and fate of fucoidan. The 
expectation that large molecules are not orally absorbed causes difficulties in understanding how Mar. Drugs 2011, 9  
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apparently systemic effects occur. Early work on digestion of fucoidan suggested that it was not 
changed by human bacterial flora and was wholly excreted [13,14]. Perhaps systemic observations are 
partly a result of prebiotic effects? Recent research indicates that there are favorable changes in 
intestinal flora after ingestion of fucoidan, including increased Lactobacilli [15,16].  
There is however, a growing body of evidence for the absorption of larger polysaccharide 
molecules such as chondroitin sulfate [17] and polyethylene glycol [18], albeit in small quantities. The 
more recent research by Irhimeh [19], Tokita [20] and Nakazato [21] strengthens the case for small 
amounts of systemic uptake from oral dosing in which the fucoidan is unchanged in the serum.  
Irhimeh used an antibody based method to detect small amounts of orally ingested Undaria derived 
fucoidan in serum in a human clinical study [19]. More recently, Tokita indicated that orally ingested 
Cladosiphon derived fucoidan can be detected in serum in a rat model [20] at levels two orders of 
magnitude lower than observed by Irhimeh. The differences in observations on the serum levels may 
be accounted for by differences in the source of fucoidan used, the time span over which the 
observations were taken (hours as opposed to days of ingestion) and the detection method (specific 
rather than cross reacting antibodies). Tokita also recorded molecular weight profiles of the fucoidan 
when absorbed, showing that fucoidan molecular weight was unchanged in serum or plasma. Lower 
molecular weight fucoidan was observed in the urine, which may indicate a hitherto unknown mammalian 
mechanism for the breakdown of fucoidan. The accumulation of sulfated polysaccharides in the 
kidney, and their urinary excretion was noted by Guimaraes in 1997 [22] although in this case, the 
fucoidan was delivered intravenously.  
Nakazato [21] examined the fate of a crude (average 28 kDa) and a higher molecular weight 
subfraction (41.4 kDa) of Cladosiphon okamuranus derived fucoidan administered in the drinking 
water at 2% w/v in a rat model, determining the concentration of fucoidan in the liver. This study 
clearly demonstrated an inhibitory effect of orally delivered higher molecular weight fucoidan on 
induced fibrosis of the liver which was associated with decreased tissue expression of transforming 
growth factor beta (TGF beta) and stromal derived factor (SDF1 also known as CXCL12), the receptor 
for CXCR4. This research was important, not only because it illustrated the fibrosis inhibitory 
potential of fucoidan, but demonstrated systemic distribution of the molecule after oral ingestion in this 
animal model. 
All of these studies have used antibody technology to either stain or quantify fucoidan. The 
increasing availability of antibodies will facilitate this type of research. Mizuno also prepared 
monoclonal antibodies that reacted with fucoidan isolated from Laminaria japonica and 
Kjellmaniella gyrate, but not with fucoidan from Undaria pinnatifida [23]. However, these were used 
only to stain for fucoidan in seaweed preparations. Earlier researchers also developed antibodies to 
Fucus vesiculosis fucoidan for botanical purposes [24]. The data are summarized in Table 1. 
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Table 1. Antibodies to fucoidan. 
Specificity 
of antibody 
Seaweed source  Trial 
Route of 
administration
Use Reference 
Heparin and 
fucoidan 
Undaria pinnatifida  Human Oral 
Estimation of serum 
uptake 
Irhimeh 
2005 [19] 
Fucoidan 
Cladosiphon 
okamuranus 
Human Oral 
Estimation of serum, 
urine concentration 
Tokita 
2010 [20] 
Fucoidan 
Cladosiphon 
okamuranus 
Rat  Oral  Staining in liver 
Nakazato 
2009 [21] 
Fucoidan 
Laminaria japonica 
and Kjellmania gyrate 
Botanical 
stain 
n/a Staining 
Mizuno 
2009 [23] 
3. Toxicology 
Fucoidan derived from all species appears to lack toxicity in vitro and in vivo. In recent toxicology 
reports, fucoidan derived from Undaria pinnatifida and Laminaria japonica was found to be safe in 
animal models at very high levels of ingestion [25,26]. The oral safety of fucoidan is echoed in clinical 
studies. Human clinical studies using orally ingested fucoidan have shown no toxicity at a dose of 1 g 
per day up to three months [27], or 3 g per day for 12 days [28,19]. It is interesting- and important-to 
note that fucoidan has substantial coagulation modifying activity in vitro. This activity was echoed in 
Irhimeh 2009 [29] in which significant decreases in global clotting time were noted after ingestion of  
3 g Undaria pinnatifida fucoidan although these stayed within the normal clinical range. Clotting times 
were increased at higher doses of 900 mg/kg body weight in a rat model with Laminaria japonica 
fucoidan [26], but intriguingly, no change in clotting time was noted in a rat model in which   
Undaria pinnatifida fucoidan at 1350 mg/kg body weight was ingested [30]. See Table 2 for details.  
Table 2. Toxicology of fucoidan. 
Fucoidan 
source 
Characteristics Studies  Dose Species  Results  Ref. 
Undaria 
pinnatifida  
53% total sugar 
7.4% sulfate 
27% Uronic acid 
54% fucose 
35% galactose 
Acute in vivo 
Ames test 
Bone marrow 
micronucleus 
1000 mg/kg 
body weight per 
day for 28 days 
Sprague 
Dawley rats 
Not toxic to 
1000 mg/kg bw;  
Increase in ALT at
200 mg/kg 
Chung 
2010 [25] 
Laminaria 
japonica 
Fucoidan Fraction  
MW average 
“10–300 kD” 
Oral dosing in 
experimental 
model; Toxicity by 
clinical observation 
Escalation doses 
up to 20 mg/kg 
Dogs with 
hemophilia A; 
Rats 
No clinical 
toxicity  
Prasad 
2008 [31] 
Laminaria 
japonica 
Fluorescent labeled 
fucoidan  
Subcutaneous  5 mg/kg  Rat  Half life 83 min 
Prasad 
2008 [31] 
Laminaria 
japonica 
MW average 189 kDa 
Fucose 28%  
sulfate 29%  
total sugasr 48% 
Acute and  
sub-chronic toxicity
300, 900 and 
2500 mg/kg bw 
to 6 months 
Wistar Rats 
Not toxic to 
300 mg/kg bw 
Prolonged clotting 
at 900 and 
1200 mg/kg bw 
Li 2005 
[26] Mar. Drugs 2011, 9  
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Table 2. Cont. 
Undaria 
pinnatifida  
64.4 ± 6.0% fucose, 
31.9 ± 4.7% galactose, 
3.6 ± 1.3% mannose, 
and 31.7 ± 2.2% 
sulfate 
Genotoxicity  
Bacterial mutation  
Bone marrow 
Micronucleus formation 
Up to 
2000 mg/kg/bw 
orally 
Sprague 
Dawley 
rats 
Fucoidan 
presents no 
significant 
genotoxic 
concern. 
Kim 2010 
[32] 
Undaria 
pinnatifida 
64.4 ± 6.0% fucose, 
31.9 ± 4.7% galactose, 
3.6 ± 1.3% mannose, 
and 31.7 ± 2.2% 
sulfate 
Toxicty measures—body 
weight, ophthalmoscopy 
urinalysis, hematology, 
and histopathology; 
Clotting paramaters; 
Prothrombin time or 
activated partial 
thromboplastin time 
1350 mg/kg 
bw/day for 
4 weeks orally 
Sprague 
Dawley 
rats 
No changes to 
No change to 
prothrombin 
time or 
activated 
partial 
thromboplastin 
time 
Kim 2009 
[30] 
Undaria 
pinnatifida 
75% fucoidan 
Full blood count,  
clinical biochemistry 
3 g per day for 
12 days 
Human 
No toxicity 
noted 
Irhimeh 
2005, 
2007, 
2009 
[19,28,29]
Fucus 
vesiculosis 
Macrocystis 
pyrifera 
Laminaria 
japonica  
75% total fucoidan 
Full blood count,  
clinical biochemistry 
0.1 and 1 g for 
84 days 
Human No  toxicity 
Myers 
2010 [27] 
Fucus 
vesiculosis 
Macrocystis 
pyrifera 
Laminaria 
japonica 
75% total fucoidan 
Full blood count,  
clinical biochemistry 
0.1 and 1 g for 
28 days 
Human No  toxicity 
Myers 
2011 [33] 
Cladisiphon sp.  85% fucoidan 
Patients with HTLV1 
were treated clinically 
6 g per day up 
to 13 months 
Human  
Four patients 
diarrhea; No 
other toxicity 
noted; 
Reduction in 
viral load 
Araya 
2011 [34] 
4. Differences between Fucoidan Fractions 
One difficulty in making comparisons within the literature lies in the many variations to molecular 
weight and composition of the fucoidan fractions used. Fractions vary widely in terms of purity, 
composition, weight and sulfation even from the same species of macroalga. As polyphenols and other 
components present in macroalgae also have bioactivity, less pure fractions can deliver confounding 
data [9,35]. Mar. Drugs 2011, 9  
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A recent multi-author paper compared fucoidans from different sources in a suite of bioassays [36]. 
Cumashi and colleagues comprehensive study uses comparable preparation techniques to generate 
samples and concentrated on commercial (or potentially commercial) sustainable sources of seaweeds. 
Their data thoroughly illustrates the common bioactivities of fucoidans and yet their differences. All 
fucoidans tested inhibited leukocyte recruitment in an inflammation model in rats. The model used 
consisted of an induced acute peritonitis in female Wistar rats and the measurement of neutrophils into 
the peritoneal cavity. Test fucoidans were delivered intravenously. Fucoidans are well known as   
L-selectin blockage agents and were found to inhibit neutrophil extravasion into the peritoneal cavity. 
Clotting parameters were also assessed. The most active inhibitors were fucoidans from Laminaria 
saccharina and Fucus evanescens, which inhibited neutrophil extravasation by more than 90% 
whereas fucoidan from Fucus distichus and Fucus spiralis inhibited the neutrophil transmigration by 
only 60%. Other parameters investigated included P selectin inhibition in a platelet aggregation model, 
coagulation parameters and cancer cell adhesion to platelets in vitro. All fucoidans, except that from 
Cladosiphon okamuranus, exhibited anticoagulant activity in vitro and in vivo. Fucoidans from 
Laminaria saccharina, Laminaria digitata, Fucus serratus, Fucus distichus, and Fucus vesiculosus 
effectively inhibited breast carcinoma cell adhesion to platelets, an effect which may point to an 
inhibition of “platelet cloaking”, a mechanism used by cancer cells to metastasise unchallenged 
throughout the body [37]. 
Others have investigated the relative effects of higher and lower molecular weight fractions of the 
same fucoidan source and found significant differences in their bioactivity. Firstly, Nakazato found 
that an orally delivered higher molecular weight fraction of fucoidan was more effective than an 
unfractionated crude fucoidan in inhibiting liver fibrosis [21]. Secondly, Maruyama confirmed that 
fucoidan is effective as an anti-tumor and immune modulating agent [38,39]. Shimizu then orally 
administered three different preparations of fucoidan from Cladosiphon okamuranus to mice [40]. The 
key findings were increases in CD8 expression in spleens of the highest molecular weight fucoidan fed 
mice. The CD4/CD8 ratio tended to decrease, and the number of cells expressing CD11b cells   
(NK, monocytes and macrophage cells) tended to increase as compared to the lower molecular weight 
fucoidan fed mice.  
Thirdly, Park examined the differential effects of high and low molecular weight fractions of 
fucoidan in an arthritis model [41]. There was a marked contrast in the two preparations. The high 
molecular weight fraction activated the inflammatory process, whereas the low molecular weight 
fraction inhibited the disease.  
Snake envenomation may be ameliorated by fucoidan (see Section 6.15. In a experiment to 
determine whether lower molecular weight would increase bioavailability of fucoidan and its 
effectiveness, Azofeifa found the reverse [42]. High molecular weight fucoidan was necessary to 
achieve the therapeutic effect against crude venom in vivo, whereas the lower molecular weight 
preparation was ineffective, despite being equally effective in vitro.  
Lastly, the way in which fucoidan is administered may make a difference to activity. This is well 
illustrated in research presented by Yanase who describes the suppression of an IgE response to 
albumin by intraperitoneal fucoidan [43]. Elevated serum levels of IgE towards common environmental 
allergens are a feature of allergic diseases such as asthma and atopic dermatitis. Having found that 
fucoidan inhibited IgE production by B cells in vitro, they studied its effect in an allergic model in Mar. Drugs 2011, 9  
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mice. In this study, the stimulated increase of plasma IgE was suppressed when fucoidan was delivered 
intraperitoneally at 100 mcg per mouse, but not when delivered orally at 10 mg per mouse. It is 
interesting to compare this to Hayashi’s study in which orally delivered fucoidan was effective in 
reducing viral titres in mice after influenza infection [44]. 
These recent examples are illustrative of the variation in fucoidan and the care that needs to be 
taken when developing a fraction for a particular application. They also illustrate remarkable bioactivity 
by molecules with low toxicity profiles. 
5. Inflammation and Fibrosis 
Inflammation can be classified as either acute or chronic. Acute inflammation, which may occur as 
a result of infection or injury, is characterized by its rapid resolution, neutrophilic inflammation and 
edema. Chronic inflammation is a response that persists for several months and is characterized by 
simultaneous inflammation, tissue remodeling and repair processes without resolution. Whilst there are 
clinically distinct fibrotic disorders they commonly start off from a persistent aggravating inflammation 
that sustains the production of matrix degrading enzymes, growth factors and cytokines, which 
gradually obliterate normal tissue architecture and cause organ damage [45].  
Acute inflammatory responses experienced after an ischemic event such as a heart attack, can be 
destructive to organs. Post ischemic organ damage results from inflammatory cascades pursuant to 
necrotic tissue. Diseases involving chronic inflammation are debilitating. Causes of inflammation are 
diverse, ranging from viral infection to systemic metabolic disorders. Chronic inflammation can 
enhance cancer metastasis and lead to increases in other disease processes. Non toxic, orally delivered 
therapeutics to address both short term and long term inflammation are highly desirable. 
Fucoidan’s potential lies in its pleiotropic anti-inflammatory effects. These include inhibition of 
selectins, inhibition of complement and enzyme inhibitory activity. 
5.1. Inhibition of Selectins 
Fucoidan is a well known research tool as a selectin blockade agent [36,46–54]. Selectins are cell 
surface receptors on white blood cells that perform a braking function for the cells, allowing them to 
roll on an organs endothelial surface and ultimately enter that tissue space. Fucoidan prevents P and L 
selectins and thus leukocyte adhesion and rolling thereby reducing inflammation in whole organs such 
as the heart, kidneys or liver. The relative selectin blocking effects of fucoidans from different sources 
was investigated by Cumashi and colleagues [36]. These are discussed earlier in this review. All fucoidans 
tested were effective at inhibiting neutrophil extravasion in a peritoneal inflammation model system.  
The selectin blockade effect has been established in vivo as a potential therapy for the prevention of 
post ischemic reperfusion injury and autoimmune cardiac injury [51]. In Tanaka’s surgical model, 
saline or fucoidan was delivered intraperitoneally to rats over 28 days with either a sham operation or 
with cardiac myosin injection to stimulate autoimmune myocarditis. The invasion of CD4-positive T 
cells into the myocardium is the initial pathology in this model. After 3 weeks, fucoidan treatment 
improved the function of the heart muscle and its weight when compared with the control. Fucoidan 
treatment decreased serum inflammatory markers, the myocarditis area and inhibited macrophage and 
CD4-positive T-cell infiltration into the myocardium.  Mar. Drugs 2011, 9  
 
 
1738
In 2010, Thomes investigated the effects of Cladosiphon okamuranus fucoidan in a model of cardiac 
infarction (i.e., a heart attack) induced by isoproterenol [52]. Oral dosing of Cladosiphon derived 
fucoidan at 150 mg/kg for 7 days had a marked protective effect on the sequelae of the infarction, 
including lowering cardiac enzymes and lipid profiles. Like many other researchers, Thomes debates 
whether the effects are via absorption or perhaps conferred via immune changes in the gut.  
In well-designed research by Kubes and colleagues, the mechanism of post ischemic organ 
protection by Fucus vesiculosis fucoidan was shown not to be a simplistic one [47]. Kubes used 
intravital microscopy to look at reperfusion of the liver after an ischemic event or endotoxin exposure. 
Fucoidan effectively inhibited neutrophil entry after ischemia but not after endotoxin exposure. Kubes 
noted that liver ischemia also leads upstream to gut ischemia and hypothesized that the protection of 
the liver was actually a result of protection of the gut, preventing downstream inflammation of the 
liver. After rerouting the circulation and removing the intestines in the rat model, fucoidan did not 
protect against neutrophil adhesion in the liver to the same degree, confirming that the protective effect 
is partly due to inhibition of inflammation in the gut.  
Most recently, experimental encephalomyelitis was reduced by administration of fucoidan [53]. 
Kim used 50 mg/kg, daily intraperitoneal administration of fucoidan into a rat to test whether it could 
either treat or prevent encephalomyelitis generated by immunization with guinea-pig myelin basic 
protein. Preventive dosing was carried out one day before immunization and the 6 days thereafter. 
Treatment dosing was carried out from the 8th to the 14th day of the disease. Surprisingly, prevention 
was not successful in contrast to treatment, which was highly effective. The lessening of clinical 
effects coincided with decreased infiltration of inflammatory cells in the affected spinal cord, probably 
partly by L selectin blockade and the suppression of specific CD4+ T cells.  
P selectin is present on platelets and assists with aggregation. Xenografting (the transplant of an 
organ from one species to another) is often complicated by abnormal clotting responses. In an attempt 
to overcome this, Alwayn [54] investigated the effects of a number of agents on xenograft induced 
clotting in a baboon model. Fucoidan from Fucus vesiculosis was very successful in inhibiting the 
platelet aggregation although the perturbation of clotting was considered problematic. Alwayn did not 
consider the potential to inhibit complement activation, although this is known limiting factor in 
xenografts [55].  
5.2. Inhibition of Complement 
Complement is a cascade system of enzymatic proteins occurring in normal serum that help to 
regulate immunity and form part of the pathogen defense system [55]. It consists of “classical” and 
“alternative” pathways that are triggered by, and combine with antibody-antigen complexes, producing 
lysis in affected cells. Complement consists of approximately 30 proteins, known as C1 to C9, with 
subtypes for each protein. Components C3 and C5 are involved promotion of leukocyte chemotaxis 
whereas C1 and C4 are involved in the specific antibody response to viruses. The alternative 
complement pathway is sequence in which C3 and C5 to C9 are activated without participation by C1, 
C2 and C4 or the presence of an antibody-antigen complex. Fucoidan fractions are very effective 
inhibitors of this cascade [55–59] being at least 40 times more potent than heparin. Mar. Drugs 2011, 9  
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Fucoidan can block the formation of classical C3 convertase. This may prevent the production of 
the pro-inflammatory anaphylatoxins and further downstream in the cascade, the C3b fragment. 
Indeed, this is one of the possible mechanisms via which fucoidan exerts an anti-allergic effect, as 
observed in diverse experimental models. 
Tissot demonstrated that fucoidan strongly binds to C1q and points out that inhibition of 
complement binding to C1q receptors present on endothelial cells could assist with xenograft (cross 
species transplants) rejection [56,57]. Indeed, fucoidan derived from Ascophyllum nodosum protected 
of porcine endothelial cells against the complement-mediated lysis that is responsible for rejection [56]. 
More recent research on xenograft protection found that Fucus vesiculosis fucoidan was useful 
inhibitor of platelet aggregation—as a result of selectin blockade, although concerns were raised over 
its temporary anticoagulant effect. Curiously, complement blockade was not considered in this 
research [54].  
Fucoidans are known to be highly branched polysaccharides but the potential meaning of the 
branching structures in terms of bioactivity was not considered until Clement’s research of 2010 [60]. 
In an elegant NMR study, Clement tackles the structural heterogeneity and the random sulfation of the 
polysaccharide chain with relation to how they affect complement binding and inhibition.   
The results suggest that branching of fucoidan oligosaccharides is a major factor in their   
anti-complementary activity at the conformational level. This work is significant as it demonstrates 
that not only molecular weight, sulfation and sugar composition affect bioactivity, but also three 
dimensional structure. When therapies from fucoidan are developed, a holistic approach to all of these 
parameters is essential. 
5.3. Inhibition of Enzymes 
Fucoidan also has significant enzyme inhibitory activity against a number of enzymes including 
matrix metalloproteases, hyaluronidases and elastases [61,62]. This inhibitory activity limits tissue 
breakdown in inflammatory settings caused by injury and disease and can even inhibit metastasis.  
Ultraviolet radiation is a prominent cause of skin photoaging and even skin cancers. It causes 
marked increases in elastase activity, breaking down elastin fibers, which accelerates loss of skin 
condition [63]. Research reported in 2009 indicates that ultraviolet radiation injury to skin fibroblasts  
in vitro, which causes increase in matrix metalloproteases and reduces procollagen levels, is markedly 
reduced by the presence of Fucus vesiculosis fucoidan [64]. Senni reported a comprehensive study on 
the inhibitory effects of fucoidan. Using human skin in ex vivo experiments he showed that fucoidan 
was able to curtail human leukocyte elastase activity which protected the elastic fibers from 
degradation [62]. A clinical study also indicated good potential for amelioration of skin aging [65]. 
Fucus vesiculosis fucoidan was applied to skin at 1% w/v twice daily for five weeks. A significant 
decrease in skin thickness and improvement in elasticity was noted compared to controls.  
According to new research by Hlawaty [66], matrix metalloprotease type 2 (MMP2) is responsible 
for intimal hyperplasia in a rat model. In this model, the aorta is damaged and the rats are treated  
via intramuscular injection with 5 mg/kg/day of a low molecular weight fucoidan derived from   
Fucus vesiculosis for two weeks. The proliferation of the smooth muscle walls which causes the 
narrowing of the lumen in the damaged vessel was measured and found to be considerably more open Mar. Drugs 2011, 9  
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in the fucoidan treated rats. Previous research has shown that this fucoidan fraction can successfully 
inhibit smooth muscle proliferation [67]. This study then looked at the enzyme activity in the vessel, 
and found that fucoidan specifically inhibited MMP2, an enzyme which degrades type IV collagen, a 
major structural component of basement membranes.  
6. Therapies from Fucoidan 
Selected applications for fucoidan based therapies are discussed in this section. Clinical data 
together with promising in vivo and in vitro data is discussed with reference to a diverse set of 
therapeutic goals.  
6.1. Osteoarthritis 
Osteoarthritis is the most common and disabling form of arthritis experienced by an increasing 
number of people as the population ages. It is characterized by a slow and progressive degeneration of 
articular cartilage. Whilst it is often regarded as a disease of “wear and tear” through ageing, 
osteoarthritis has a strong genetic component and is also affected by injury and by diseases such as 
obesity. In addition to the cartilage itself, osteoarthritis also involves the surrounding tissues, including 
the synovium and the subchondral bone. Osteoarthritis has an inflammatory component, and 
undoubtedly, a powerful tissue breakdown component which result in pain and stiffness [68].  
Several recent studies indicate a role of fucoidan in addressing the symptoms of osteoarthritis.  
Park et al. used an animal model of collagen induced arthritis, and showed that orally administered 
Undaria pinnatifida fucoidan successfully inhibited pain [41]. In a small human clinical study, 
osteoarthritis symptoms were significantly inhibited by oral administration of fucoidan rich seaweed 
extract. Over three months, symptoms were reduced by 52% [27]. This result is a marked improvement 
for osteoarthritis symptoms. There was no reduction in TNF alpha which was used as inflammation 
marker, but an accompanying study in healthy volunteers showed a decrease in Interleukin 6, a marker 
for chronic inflammation [33].  
The mechanism for the clinically observed reduction in pain of osteoarthritis is unclear. Was pain 
decreased by the blockade of neutrophils? Cunha showed that fucoidan successfully blocked the 
accumulation of neutrophils and pain nociception in an animal model [69]. Cunha’s study emphasized 
the importance of neutrophils as an originator of inflammatory hypernociception and confirmed that 
fucoidan blocks the accumulation of neutrophils by selectin blockade in their model. See Table 3. 
Table 3. Arthritis and fucoidan. 
Fucoidan Model  Adminstration  Observation  Reference 
Fucus vesiculosis 
Macrocystis pyrifera 
Laminaria japonica 
Human clinical   Oral daily 100 mg or 
1000 mg for 
three months 
No toxicity 
Up to 52% reduction in 
symptoms 
Myers 2010 
[27] 
Fucus fucoidan 
(Sigma) 
Mouse with surgical 
destabilization of the 
medial meniscus 
20 mg/kg 
intraperitoneal 
injection 
Fucoidan suppressed 
cellular infiltration of joint 
and suppress 
post-operative (3 days), but 
not late (16 weeks) pain 
Mcnamee 
2010 [70] Mar. Drugs 2011, 9  
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Table 3. Cont. 
Fucus fucoidan 
(Sigma) 
Wistar rats with 
carrageenan induced 
local inflammation in 
the footpad 
20 mg/kg 
intravenously 
Fucoidan inhibits 
mechanical 
hypernociception and 
neutrophil migration  
Cunha 2008
[69] 
Undaria pinnatifida 
fucoidan 
Collagen induced 
arthritis in mice 
100 kDa, 3.5 kDa and 
1 kDa fractions orally 
administered daily  
300 mg/kg to 49 days
1 kDa fraction effectively 
inhibited whereas 100 kDa 
exacerbated disease 
Park 2010 
[41] 
6.2. Surgical Adhesions 
As identified earlier, fucoidan is a potent selectin blocker, and can therefore inhibit inflammatory 
damage, such as that caused by post-ischemic inflammation. A fibrotic reaction after the inflammation 
is responsible for a condition called “surgical adhesions”. This condition is a disabling result of minor 
damage during abdominal surgery or sometimes after infections. Small injuries cause inflammatory 
responses on the external surfaces of the bowel which generate the fibrotic response, leading to areas 
in which the bowel becomes tied to the peritoneal wall or to other parts of the bowel. Products aimed 
at reducing post surgical adhesions have variable levels of success. Now techniques have been 
developed using fucoidan as an ingredient in a film format [71]. In Cashman’s 2010 study, a 
Fucus vesiculosis fucoidan loaded film inhibited the number of adhesions in a rabbit model by up to 
90%. The effective level of fucoidan loading in the film was in the range of 0.33% to 33% w/w and no 
toxicity was observed.  
6.3. Liver Fibrosis 
Liver fibrosis occurs after toxic or pathogen insult to the liver. The function of the liver is 
compromised as the fibrous tissue takes over from active liver cells and significant morbidity may 
ensue. Several recent publications indicate that fucoidan has protective effects against liver damage by 
inhibiting fibrosis and this can be achieved by oral dosing in the models tested.  
In damaged or diseased livers, hepatic stellate cells proliferate into fibrous masses whereas 
functional hepatic cells expire. Hayashi’s 2008 research into carbon tetrachloride induced liver injury 
showed that fucoidan was a highly effective inhibitor of this type of fibrosis [72]. Saito used an 
alternative liver damage model (Concanavalin A), but used the same type of Fucus vesiculosis 
fucoidan [73] intravenously to inhibit the damage.  
Nakazato’s research used a different model of liver damage, but illustrated a profound inhibition of 
damage by orally delivered high molecular weight fractions of Cladosiphon okamuranus fucoidan [21]. 
Both crude (28 kDa) and high molecular weight (41.4 kDa) fucoidan fractions were delivered at 2% w/v 
in drinking water over 12 weeks. The high molecular weight fraction was a powerful inhibitor of  
N-nitrosodiethylamine (DEN) induced liver fibrosis as measured by histology and staining. There was 
a strong down regulation of TGF beta and SDF1 expression in the liver as compared to the controls. 
D-galactosamine-induced hepatopathy is used as a model for liver disease because it resembles 
acute viral hepatitis [74]. Kawano had previously identified therapeutic potential of edible whole Mar. Drugs 2011, 9  
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seaweeds in the diet of experimental rats with this type of liver damage [75]. In his 2007 study he 
identified the components of the seaweeds that gave rise to the inhibition of liver disease. The elevated 
levels of aspartate and alanine aminotransferases were inhibited specifically by the fucoidan in the diet 
at levels equivalent to those in whole seaweed at 5% of the total diet [75,76]. Lastly, Hayakawa 
addressed the issue of hepatocarcinoma in ex vivo samples of chronic cirrhosis and hepatitis B and C 
from a clinical setting and found that Fucus vesiculosis fucoidan has a potentially therapeutic effect [77]. 
To conclude, fucoidan appears to have good potential as an orally delivered adjunct therapy for 
liver disease. See Table 4 for details. 
Table 4. Liver disease and fucoidan. 
Fucoidan Model  Treatment  Result Ref. 
Fucus vesiculosis 
fucoidan (Sigma) 
Concanavalin induced 
liver injury in mice  
1–30 mg/kg 
intravenously 30 min 
before concanavalin A 
Significantly inhibited 
raised levels of TNF-alpha 
and IFN-gamma. Increased 
endogenous IL-10 
production 
Saito 
2006 [73]
Fucus vesiculosis 
fucoidan (Sigma) 
CCl4 induced liver 
fibrosis in mice 
fucoidan (50 mg/kg body 
weight) administered 
intraperitoneally for 
8 weeks 
Protection of normal 
hepatocytes. Inhibition of 
hepatic stellate cell 
proliferation 
Hayashi 
2008 [72]
Cladosiphon 
okamuranus 
fractions Crude 
(28 kDa) and 
HMW (41.4 kDa) 
N-nitrosodiethylamine 
(DEN) induced liver 
fibrosis model in 
Sprague dawley rats 
2% fucoidan in drinking 
water for 12 weeks 
Protection from damage 
Increased metallothionein 
Down regulation of  
TGFbeta 1 and SDF1 
Nakazato 
2010 [21]
Fucus vesiculosis 
fucoidan (Sigma) 
Ex vivo human hepatoma 
(hepatitis B and C) and 
Cirrhosis  
Inhibition of biotidinase 
in tissue samples was 
assessed 
Fucoidan decreased the 
disease elevated activity of 
biotinidase 
Hayakawa
2009 [77]
Fucus vesiculosis 
fucoidan (Sigma) 
Rats with  
D-galactosamine-induced 
hepatopathy  
Dietary inclusion of 
~1.2% fucoidan for 
8 days 
Fucoidan was protective 
against D-galactosamine-
induced hepatopathy in rat 
Kawano 
2007 
[75,76] 
6.4. Radiation and Fucoidan 
Radiation causes a number of potential harms. Firstly, uptake of radioactive substances into the 
body perpetuates radiation damage, especially in children. Secondly, radiation damage itself causes 
cell death. This is particularly dangerous in that immune cells can be completely eliminated. The 
hemopoeitic stem cells that repopulate the immune system arise in the bone marrow and are called 
bone marrow stem cells. The protection of this progenitor population is very important in both medical 
and emergency settings. 
Whole seaweed and seaweed extracts, particularly alginate, have been ingested as moderators of 
radiation damage [78]. The decontaminating effects of alginate syrups and additions to breads and 
milks have been known about for many years [79]. Alginate is used as a syrup useful in both reducing 
uptake of radioactive elements and increasing their excretion or “decorporation” [80]. Whilst iodine is Mar. Drugs 2011, 9  
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a naturally occurring component and regular ingestion would assist in maintaining thyroid saturation, 
well timed and high levels of iodine in the form of sodium iodide are required to prevent uptake of 
radioactive isotopes of iodine.  
Fucoidan, although a chelating agent, has not been recognized as a decorporation agent for 
radionuclides. It has, however, been demonstrated to provide radiation protection in both in vitro and 
mouse models [81,82]. Fucoidan was known to stimulate the maturation of dendritic cells, which are 
potent antigen-presenting cells in the immune system [83]. Byon measured the expression levels of cell 
surface markers in bone marrow stem cells after radiation. In this study the fucoidan was delivered 
intraperitoneally prior to radiation. As bone marrow is the main cellular source for the hematopoietic 
and immune systems, it contains large numbers of lymphocytes, granulocytes, and stromal cells as 
precursors and mature cells. Their results suggested that a specific population of cells—granulocytes—
may selectively survive in response to fucoidan treatment following irradiation [82].  
In irradiated mice the optimal intraperitoneal pre-treatment dosage of fucoidan to maximise survival 
was determined to be 100 mg/kg delivered into the peritoneal cavity [81]. Rhee also demonstrated the 
potential for protection from gamma irradiation in mice and in vitro [83]. Laminaria japonica derived 
fucoidan delivered intraperitoneally at 100 mg/kg was found to protect against changes in the counts of 
blood cells. Several parameters indicated better recovery after irradiation. The erythrocyte count in the 
irradiated controls ranged from 64% to 67% but the fucoidan-treated group increased gradually, 
ranging from 75% to 80%. The mean number of survival days and the 50-day survival rate in this 
group was 29 days and 30% at the highest fucoidan dose of 100 mg/kg as compared to 9 days and 0% 
for the control group. 
6.5. Stem Cells and Fucoidan 
Fucoidan is a known stem cell mobilizer when delivered intravenously. It has also shown activity 
then delivered orally [28]. When delivered intravenously, Fucus vesiculosis fucoidan is highly effective 
in mobilizing stem cells into the peripheral circulation in baboons and mice. The mechanism of 
mobilization appears not to relate solely to the inhibition of selectin binding but also to fucoidan’s 
ability to bind to SDF1 (CXCL12) [84,85]. Stem cell mobilization is used as a method of collecting 
sufficient immune repopulating cells from the peripheral circulation that are stored and re-engrafted 
after chemotherapy and radiotherapy in selected cancer patients.  
SDF1 binds to the G protein coupled CXCR4 receptor, which has SDF1 as its unique ligand. 
CXCR4 is expressed by some hemopoietic stem cells, most leukocyte populations, endothelial cells, 
epithelial cells and some carcinoma cells. This SDF1/CXCR4 affiliation is thought to be involved not 
only in the regulation of stem cell release and homing, but also in some disease processes, including 
fibrogenesis [85].  
The binding of fucoidan to SDF1 was found to block liver regeneration in an animal model [86]. 
This outcome contrasts with the marked radiation protection of hemopoietic stem cells by fucoidan 
described in Section 6.4 and the effective use of fucoidan in the inhibition of liver disease in a number 
of animal models as described in Section 6.3. In Mavier’s example, Fucus vesiculosis fucoidan was 
delivered intraperitoneally to rats at 25 mg/kg body weight. The liver was entirely damaged, both 
chemically and physically, and regeneration was observed. Under less dramatic circumstances, the Mar. Drugs 2011, 9  
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liver regenerates from mature differentiated cells but when injured or after partial hepatectomy 
combined with inhibition of mature hepatocyte proliferation, regeneration is achieved from liver stem 
cells, which are known as “oval cells”. In the control damaged rats, oval cell accumulation could be 
seen, but in fucoidan treated rats, the oval cell numbers were severely depressed.  
Oral delivery of Undaria pinnatifida fucoidan in a clinical observational study also resulted in  
an increase in the number of stem cells, of serum levels of SDF1 and the expression of CXCR4  
on stem cells (CD34+) [28]. This observation correlates with the in vitro and animal studies showing 
that fucoidan mobilizes stem cells, although the degree of mobilization was not as large at the   
time point measured. The increase in CXCR4 expression could in some way reflect the binding of 
SDF1 by fucoidan.  
Lastly, oral delivery of a seaweed extract in a clinical study consisting of a blend of Fucus vesiculosis, 
Macrocystis pyrifera and Laminaria japonica fucoidans increased phagocytosis by granulocytes and 
macrophages [33] in addition to NK and cytotoxic T cell numbers. Additionally the chronic 
inflammation marker interleukin 6 was lowered. This data has common features with an animal study 
carried out by Shimizu [38] and may point to the potential for radiation protection potential by orally 
delivered fucoidan. 
6.6. Blood Homeostasis 
It is beyond the scope of this review to consider the entire recent research on fucoidan fractions and 
blood homeostasis. In brief, fucoidan compounds have a retarding effect on coagulation in part due to 
interference with antithrombin III and heparin cofactor II [87]. The in vivo effects of intravenous 
delivery of most types of fucoidan are to extend global clotting time, an effect which is reversible [36]. 
Kwak recently investigated Fucus vesiculosis fucoidans inhibitory effect in a ferric chloride induced 
thrombosis model in mice [88]. Fucoidan showed a stronger antithrombotic effect than heparin.   
The anti-thrombin and anti-factor Xa activities of fucoidan in vitro were less than those of heparin, 
which implies that the antithrombotic activities are due to binding with heparin cofactor II rather than 
with antithrombin. 
Pomin addresses the issues of strong anticoagulant activity of fucoidans by desulfation,   
producing fractions with desirable bioactivity unfettered by anticoagulant behaviors [89]. A linear 
sulfated fucoidan from sea urchin egg jelly required significantly longer chains than mammalian 
glycosaminoglycans to achieve the same anticoagulant activity. A slight decrease in the molecular size 
of the sulfated fucan dramatically reduced its effect on thrombin inactivation mediated by heparin 
cofactor II. A sulfated fucoidan with 45 tetrasaccharide repeating units was able to bind to heparin 
cofactor II but was unable to link efficiently the plasma inhibitor and thrombin, which required 
fucoidan with 100 or more tetrasaccharide repeating units. 
A recent clinical study examined the effects of orally ingested fucoidan on clotting times. 3 g of 
Undaria pinnatifida fucoidan were ingested daily for 12 days by healthy subjects [29]. A significant 
prolongation of global clotting time was noted but this was within normal clinical parameters. 
Toxicological studies on Undaria pinnatifida fucoidan in rats showed no effect on clotting times, even 
at very high doses [25]. A toxicology study on Laminaria japonica fucoidan did show some pertubations 
in clotting at 900 mg/kg [26], far above the dose used in the clinical study.  Mar. Drugs 2011, 9  
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More recent research into activity illustrates the somewhat counter-intuitive “procoagulant” effect 
of fucoidan in hemophilia model [31]. In hemophilia A dogs, orally delivered Laminaria japonica 
fucoidan fraction improved clotting times, perhaps by creating a bypass in the normally blocked 
clotting pathway. 
6.7. Neuronal Protection 
Increasing interest in reducing or reversing brain ageing and disease has seen many agents assessed 
for their effects on neurons and brain function. Alzheimer’s is a brain disease that causes significant 
and highly distressing loss of function. It is characterized by the accumulation of beta amyloid plaques 
in the brain tissue. It has been hypothesized that Alzheimer’s is associated with Herpes infections in 
the central nervous system [90]. The relatively large size of fucoidan precludes penetration of the 
blood brain barrier but as noted below, systemic administration was effective in maintaining neuronal 
function in a mouse model.  
Fucoidan shows promise in protecting brain function in a number of ways. It has been 
comprehensively assessed by Jhamandas [91] for effects on current in whole rat brain neurons and also 
on the neurotoxic effects caused by beta amyloid in primary culture neuronal cells. Fucus vesiculosis 
fucoidan at one micromolar concentration could inhibit currents by 15%. It was also able to reverse the 
current blocking effects of beta amyloid. Fucoidan did not inhibit the aggregation of beta amyloid,  
but did protect primary cultures of rat basal forebrain cholinergic neurons, against amyloid induced 
cell death. 
Cui’s recent research centered on a lipopolysaccharide (LPS) activated microglial cells [92]. 
Microglia are usually resting cells in the brain, but if activated, for example by LPS, they change 
shape, become active and secrete inflammatory mediators and nitric oxide (NO). If too much 
activation takes place, surrounding neuronal cells die, instigating more inflammation and beginning a 
cycle of neurodegeneration. 62.5 mcg/mL fucoidan was able to prevent shape change in the LPS 
exposed microglial cultures, and 125 mcg/mL inhibited NO production. In 2004 Li demonstrated the 
characteristic fragmented DNA (fDNA) observed in neuronal nuclei in Alzheimer brain was taken up 
by adjacent activated microglia which then became activated [93]. Blocking the scavenger receptors on 
the microglial cells with Fucus vesiculosis fucoidan at 40 ng/mL suppressed this uptake.  
Pei also demonstrated the scavenger receptors on microglial cells could be successfully blocked by 
fucoidan [94]. Huang [95] used time lapse recording to investigate how microglia are involved in the 
growth of amyloid plaques. Fucus vesiculosis fucoidan at 10 micromolar concentration was able to 
inhibit the amyloid induced microglical clustering effect that gave rise to plaques. Do presented a 
study on tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) induced NO 
production in glioma cells [96]. Fucoidan inhibited NO production in this model system via a number 
of signaling pathways.  
Luo, from the same research team as Cui, investigated the effects of the same Laminaria japonica 
fucoidan fraction in a model of Parkinson’s disease in mice [97]. Mice were given fucoidan at a dose 
rate of 12.5 mg/kg or 25 mg/kg, intraperitoneally daily for 18 days. The Parkinson’s inducing agent 
was given on the 11th day an hour after injection of fucoidan. There was a clear dose dependent Mar. Drugs 2011, 9  
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protection by fucoidan at 25 mg/kg body weight, including inhibition of lipid peroxidation, enzyme 
functions and glutathione levels. See Table 5. 
Table 5. Brain cells and fucoidan. 
Fucoidan type  Model  Effects  Reference
Fucus vesiculosis 
fucoidan (Sigma) 
Rat neuron in vitro  Inhibits neurotoxic effects of amyloid 
Jhamandas 
2005 [91] 
Laminaria japonica 
fuucoidan average 
MW 7000 
Lipopolysaccharide 
activated microglial cells 
in vitro 
Inhibits NO production in LPS activated 
microglial cells 
Cui 2010 
[92] 
Sea cucumber 
fucoidan 
Neuronal stem cells  
in vitro 
Protection from radiation 
Zhang 2010 
[98] 
Laminaria japonica 
fuucoidan average 
MW 7000 
MPTP-induced 
Parkinsonism in mice  
Fucoidan delivered IP 
Protects against Parkinsons disease model 
of neuronal damage 
Luo 2009 
[97] 
Fucus vesiculosis 
fucoidan (Sigma) 
Microglial cells in vitro  
Fucoidan completely blocks microglial 
uptake of fDNA at only 40 ng/mL 
Li 2004 
[93] 
Fucus vesiculosis 
fucoidan (Sigma) 
In vitro microglial 
clustering assay 
Fucoidan inhibits beta amyloid induced 
microglial clustering at 10 µM 
Huang 2009
[95] 
Fucus vesiculosis 
fucoidan (Sigma) 
Microglial cells in vitro  
Inhibits LPS uptake into microglia by 
scavenger receptors  
Pei 2007 
[94] 
Fucus vesiculosis 
fucoidan (Sigma) 
Glioma cells in vitro 
Fucoidan inhibits TNF-alpha- and  
IFN-gamma-stimulated NO production via 
p38 MAPK, AP-1, JAK/STAT and IRF-1 
Do 2009 
[96] 
Fucus vesiculosis 
fucoidan (Sigma) 
NO production in neuronal 
blastoma cells in vitro 
Fucoidan has protective effect via inducible 
nitric oxide synthase (iNOS) 
Lee 2007 
[99] 
6.8. Viruses: Influenza, Herpes and Dengue 
Inhibitory effects of fucoidan on coated viruses are well known and were well reviewed a decade 
ago by Schaeffer [100]. Fucoidans have no direct pathogen killing activity but rather, they inhibit 
infection via receptor entry blocking and interference with replicative processes. Other sulfated 
polysaccharides in addition to fucoidans have been known to possess inhibitory activity against coated 
viruses such as Herpes and HIV [100–102]. In the case of viruses, receptor blocking activity prevents 
viral cell entry and there may also be inhibition of viral replication and syncytia (giant cell) formation. 
Drawbacks to using fucoidan as an orally delivered agent remain those of bioavailability. However, 
pathogens targetable from the lumen of the gut, such as viruses harbored in gut immune structures, 
may be particularly well targeted by oral fucoidan. As the following examples illustrate, oral dosing 
does have protective effects against viral infection.  
Influenza epidemics have become topical in recent years with outbreaks of Influenza A causing 
significant global concern. Existing therapies can become useless as resistance develops. Several research 
groups have investigated inhibitory effect of fucoidan fractions on clinical strains of influenza [103] 
and para-influenza [104] in vitro. Undaria pinnatifida has a marked inhibitory effect on the recent H1N1 
influenza A virus with half maximal effective inhibitory concentrations at less than 1 mcg/mL [44]. Mar. Drugs 2011, 9  
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Notably, these effects can also be seen in vivo with orally delivered fucoidan. Hayashi reported mouse 
model data in which 5 mg per day orally delivered Undaria pinnatifida fucoidan strongly inhibited 
influenza A infection [44]. It had a marked synergistic effect with oseltamivir, a neuraminidase 
inhibitor effective in treating influenza. Even as a sole agent, fucoidan was able to significantly reduce 
viral titres in the lung of infected mice. At the time of writing, there are no clinical studies on Influenza 
using fucoidan reported in the available literature. 
Herpes infections can be debilitating and recurrent. There is a need for a both treatment and 
prevention strategies for both Herpes 1 and 2. In a small clinical case study series, Herpes reactivation 
was inhibited by ingesting a fucoidan rich Undaria pinnatifida preparation [105]. Undaria pinnatifida 
fucoidan was shown to be a highly effective inhibitor of clinical strains of Herpes entry to cells in 
culture [102,106] at microgram concentrations. Interestingly, stains resistant to the common drug 
therapy, acyclovir, were equally well inhibited. Hayashi established that the inhibitory effect of 
fucoidan was carried over to in vivo setting in a mouse model [101]. In his research, orally delivered 
Undaria pinnatifida fucoidan exerted protective effects via direct inhibition of viral replication and 
stimulation of both innate and adaptive immune defense functions. Oral administration of the fucoidan 
at 5 mg/day every 8 h (three times per day) from 1 week before virus inoculation to 1 week   
post-inoculation (pretreatment), or for 1 week after virus inoculation protected mice from infection 
with HSV-1 and enhanced cytotoxic T cell activity. NK cell activity was improved in HSV-1-infected 
immunosuppressed mice. The production of neutralizing antibodies in the mice inoculated with HSV-1 
was significantly promoted by the oral administration of the fucoidan for 3 weeks.  
Dengue virus is a debilitating viral infection spread by mosquitoes. Sometimes known as ‘bone 
crack fever’ for its painful joint effects, it has four different subtypes. Infection by one does not confer 
protection from infection by another type. There are no treatments for dengue other than pain relief and 
good nursing. Fucoidan from Cladosiphon has been shown to inhibit type 2 dengue in vitro [107]. 
Given the effectiveness of oral fucoidan in inhibiting Herpes, there may be potential in further research 
into the inhibitory effects of fucoidan fractions on Dengue fever. At the time of writing, there are no 
clinical studies on dengue using fucoidan reported in the literature.  
6.9. Viruses: HTLV1 
In a clinical “first” this year, Araya presented data on orally delivered fucoidan to treat Japanese 
subjects infected with Human T lymphotropic virus type-1 (HTLV-1) [34]. This human retrovirus 
causes HTLV-1associated myelopathy/tropical spastic paraparesis (HAM/TSP) and is also responsible 
for adult T cell leukaemia in a small number of infected subjects. A higher viral load in individuals 
with HTLV-1 infection increases their risk of developing and the clinical progression of HAM/TSP 
and unpleasant and increasingly disabling condition. In vitro studies by Japanese and Brazilian 
researchers have indicated that fucoidan from Cladosiphon okamuranus, and fucoidan containing 
water extracts from Sargassum vulgare and Laminaria abysslis were effective at inhibiting HTLV-1 
viral infection in cell culture [108,109]. Although the extracts were not selectively toxic to infected 
cells, syncytia formation and thus cell to cell transfer of the virus was inhibited. In Araya’s 2011 study, 
the in vitro inhibitory effect of fucoidan on cell-to-cell HTLV-1 infection was confirmed by using 
luciferase reporter cell assays.  Mar. Drugs 2011, 9  
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In Araya’s open-label trial, 13 patients with HAM/TSP were treated with 6 g of a relatively pure 
(85%) Cladosiphon okamuranus derived fucoidan daily for 6–13 months. HTLV-1 proviral DNA load 
was measured and found to decrease by 42.4% on average over the trial period. Interestingly, there was 
variation in the trial subjects with some achieving much greater reductions. Araya also measured 
immune cell function, as fucoidans are known to modulate immune function in other animal [38–40,53] 
and clinical studies [33,53]. Frequencies of HTLV-1-specific CD8(+) T-cells, natural killer cells, 
invariant natural killer T-cells and dendritic cells in the peripheral blood were analyzed but did not 
show significant changes. This contrasts with research in which fucoidan intake did alter immune 
parameters [33,40]. In this clinical study, there were mild side effects. During the treatment 
four  patients with HAM/TSP developed diarrhea, which improved immediately after stopping 
fucoidan administration. 
6.10. Leishmaniasis 
Leishmaniasis is a protozoan parasite spread by the bites of sandflies. As many as 12 million people 
are believed to be currently infected, with about 1–2 million estimated new cases occurring every  
year [110]. There are many different types of leishmaniasis, most being spread from animal to humans, 
but some species are also spread between humans. Leishmaniasis most commonly manifests as a skin 
disease causing ulcers but may also spread to organs, a condition known as “visceral leishmaniasis” 
and can be fatal. There are no vaccines for leishmaniasis, and one older treatment, sodium antimony 
gluconate, is no longer effective in India.  
In 2011, Kar published research in which fucoidan was administered in a rat model to treat 
Leishmaniasis [111]. Whilst the authors are cautious about the extrapolation of their work to humans 
and to other types of leishmaniasis, the potential for an adjunct or even a sole therapy is strong. Their 
data showed inhibitory effects on amastigote (part of the life cycle of leishmaniasis) multiplication 
within macrophages. There was complete elimination of liver and spleen parasite burden at   
200 mg/kg/day given orally, 3 times weekly, in a 6-week mouse model of both antimony-susceptible 
and -resistant strains. They noted switching of immune defense from a Th2 to Th1 mode and increased 
splenocyte superoxide and NO production. IL-10 and TGF beta, both Th1 suppressive cytokines, were 
found to be profoundly down-regulated in infected fucoidan-treated mice. TGF beta, was found to be 
significantly down-regulated in fucoidan-treated mice. Most importantly, fucoidan was thought to be 
curative when administered orally 15 days post-infection. 
At the time of writing there are no published clinical studies involving fucoidan and 
leishmaniasis infections.  
6.11. Malaria 
According to the World Health Organization, in 2008, there were 247 million cases of malaria and 
nearly one million deaths. Malaria is caused by four different types of Plasmodium parasites. The 
parasites are spread to people through the bites of infected Anopheles mosquitoes, called “malaria 
vectors”. If resistance to the currently effective artemisinin drugs develops and spreads to other large 
geographical areas, as has happened before with chloroquine and sulfacoxine-pyrimethamine the Mar. Drugs 2011, 9  
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public health consequences could be grim, as no alternative antimalarial medicines will be available in 
the near future.  
The malaria parasites (Plasmodium merozoites) enter the blood stream and must then penetrate a 
red blood cell (erythrocyte) in order to multiply. The cell bursts and the cycle begins again. Malaria 
leads to severe anemia and cycles of fever as the parasite takes hold. Fucoidan is one agent that shows 
some promise as an inhibitory agent for Plasmodium infection in vitro and in mouse models [112]. 
Undaria pinnatifida fucoidan significantly inhibited the invasion of erythrocytes by Plasmodium 
falciparum merozoites. Four-day suppressive testing in Plasmodium berghei-infected mice (a model 
system) with fucoidan resulted in a 37% suppressive effect versus the control group and a significant 
delay in the deaths from anemia.  
At the time of writing, there are no clinical studies on malaria using fucoidan reported in the 
available literature. 
6.12. Prions 
Transmissible spongiform encephalopathies or “prion” diseases are a group of fatal neurodegenerative 
disorders. They include the human diseases “Kuru” and Creutzfeldt-Jakob disease (CJD), the sheep disease 
scrapie, and bovine spongiform encephalopathy which affects cattle. ‘Kuru’ occurs among people from 
New Guinea who practiced a form of cannibalism in which they ate the brains of dead people as part of 
a funeral ritual. This practice stopped in 1960, but cases of Kuru occurred for decades because of the 
long incubation period [113,114]. These diseases are characterized by accumulation of an abnormally 
folded prion protein in the central nervous system and the lympho-reticular system. Recently, variant 
CJD became a major health concern in Europe after infected meat entered the food chain. 
Prions remain a therapeutic challenge with no approved preventative or curative drug therapy available. 
Doh-Ura and colleagues examined the effects of fucoidan ingestion on prion infection in a mouse 
model and illustrated that prior ingestion of fucoidan could inhibit the development of disease [115]. 
Fucoidan orally administered to the mice after the enteral inoculation delayed the disease onset for 
about half the time of the control incubation. However fucoidan administered before enteral inoculation 
did not affect the incubation time. As fucoidans are large molecules, the blood brain barrier is unlikely 
to allow passage into the central nervous system. It is perhaps more likely that fucoidan exerted effects 
via the gut immune system. To date there are no reported clinical studies with fucoidan to assess 
effects on prion infections.  
6.13. Helicobacter and Stomach Ulcers 
A recent encouraging clinical study was carried out in Indonesia to determine the effectiveness of 
fucoidan therapy for Helicobacter pylori affected patients [116]. This study was supported by 
considerable in vitro and in vivo evidence to suggest that fucoidan has inhibitory effects on 
Helicobacter infections, largely by inhibiting adhesion to mucosal surfaces [117]. Juffrie’s study 
included patients with at least eight years of abdominal pain or dyspepsia. After endoscope confirmation 
of ulceration and Helicobacter infection, subjects took placebo or 100 mg Cladosiphon okamuranus 
fucoidan daily for three weeks before undergoing another endoscopy which included a biopsy. There 
was relief from symptoms such as pain and vomiting in the fucoidan treated patients from 5 days into Mar. Drugs 2011, 9  
 
 
1750
the study. At biopsy, the majority of the patients with severe ulcers who received fucoidan at 100 mg 
per day for three weeks changed to the healing stage or scarring stage whereas only 37.5% patients 
who received placebo changed to the healing stage.  
In animal models, aspirin induced ulceration (a model for gastric ulcers) could be inhibited   
by orally delivered Fucus vesiculosis fucoidan at dose rates of 20 mg/kg body weight/day for 
two weeks [118]. Aspirin treatment generated the expected rises aspartate and alanine transaminases 
(AST and ALT) and the serum cytokines IL6, IL10 and IFN gamma. Oral fucoidan showed 
considerable (p < 0.05) protection against ulceration by inhibiting the acute alterations of AST, ALT, 
cytokines and stomach glycogen. However, aggravated serum INF-gamma was observed in the 
fucoidan-pre-treated group [118]. 
6.14. Renal Disease and Hyperoxaluria 
Fucoidan may act in several ways to protect against kidney damage. As for other organs in the post 
ischemic stage, reperfusion injury may be protected by Fucus vesiculosis fucoidan administration at  
10 mg/kg intravenously on the basis of its ability to inhibit P selectin [119]. Zhang demonstrated  
the effects of up to 200 mg/kg body weight orally administered Laminaria japonica fucoidan in   
the prevention of chronic renal failure or Heymann nephritis (an autoimmune condition) in a rat   
model [120,121]. 
Elevated levels of oxalate in serum are commonly associated with the painful joint swellings known 
as gout. Elevated oxalate levels are also responsible for kidney stones. In 2007, Veena assessed   
Fucus vesiculosis fucoidan in Wistar rats in which hyperoxaluria and calcium oxalate deposition in the 
kidneys was induced by ethylene glycol [122]. Daily doses of 5mg/kg body weight were administered 
subcutaneously over 28 days, after which tissues were harvested for assessment. Fucoidan successfully 
normalized the disturbances associated with hyperoxaluria. Josephine, from the same research group, 
published additional research in which the effects of fucoidan on Cyclosporine A (CsA)-induced 
nephrotoxicity were assessed [123]. A dose of 5 mg/kg body weight fucoidan isolated from Sargassum 
wightii or Fucus vesiculosis was administered subcutaneously over 21 days. Both fucoidans protected 
mitochondrial function and other biological measures to the same degree. The reasoning behind the 
model was the therapeutic use of cyclosporine. Cyclosporine is a useful immunosuppressive during 
transplants yet its nephrotoxicity curtails the degree of its use. 
6.15. Snake Envenomation 
Snake bite is a seriously neglected issue affecting Central and South America, parts of Asia and 
Africa [124–126]. Existing therapy for snake bites consists of anti-venoms. These can be costly, have  
a limited shelf life and also require careful storage. They are not always available in areas of   
greatest need.  
Snake venoms are a complex mixture that may cause swelling, bleeding, blistering, and ultimately 
skin and muscle necrosis. In bites from commonly occurring South American snakes these effects are 
caused by two major components of the venoms; zinc dependent metalloproteinases and myotoxic 
phospholipases (PLA2). The metalloproteases degrade extracellular matrix components, such as the 
collagens that make up microvessel structures. The myotoxic phospholipases break down the plasma Mar. Drugs 2011, 9  
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membrane of skeletal muscle cells. A large inflammatory reaction ensues with infiltration of leukocytes. 
Swelling follows, which can cause restricted blood flow, ischemia and further tissue damage.  
Fucoidan from Ascophyllum nodosum was been investigated by Costa Rican research teams   
and was found to be an effective inhibitor of PLA2 variants present in the venoms of crotalid   
snakes [124–127]. Crotalid snake venom damages the lymphatic system via the enzyme PLA2. Mora 
demonstrated that the potent PLA2 inhibitory effects of fucoidan could completely eliminate the 
myotoxic effects of the venom if preincubated with it prior to injection in a mouse model, but it did not 
change the hemorrhagic effects of the venom [125]. Angulo demonstrated that fucoidan forms 
complexes with the snake venom PLA2 and inactivates them [127]. 
In Rucavado’s most recent study [124], the effect of fucoidan combined with batimastat   
(a peptidomimetic hydroxamate metalloproteinase inhibitor known to inhibit crotalid venom activity) 
was investigated in a mouse model. Fucoidan reduced the presence of intracellular proteins in exudates, 
whereas batimastat reduced the amount of relevant extracellular matrix proteins. The combination of 
these inhibitors resulted in the elimination of the most relevant pathological effects of this venom.  
Curiously, lowering the molecular weight of the fucoidan to theoretically enhance bioavailability 
was not effective in inhibiting snake venom [42]. A study evaluated the ability of two fractions of 
Ascophyllum nodosum fucoidan to prevent muscle necrosis when rapidly administered after injection 
of a purified myotoxin or crude venom in a mouse model. The two preparations were standardized to 
the same neutralizing potency. Local administration into the muscle of either fraction after myotoxin 
injection prevented nearly 50% of muscle necrosis. However, when tested against crude venom (which 
contains several myotoxin isoforms), muscle injection of the higher molecular weight fraction 
inhibited myonecrosis by nearly 50% as compared to the untreated group. In contrast to expectations, 
the use of smaller fucoidan fragments reduced rather than increased the therapeutic response. This may 
relate to a particular structural feature in the high molecular weight fraction that is absent in the lower 
molecular weight fraction. 
In 2003, Vasanthi described the successful inhibition of cobra snake venom in a mouse model by 
intraperitoneal administration of an extract from Padina boergensii [128]. However, the extract was 
prepared with methanol, and it is unclear whether fucoidan was a major component of the extract as 
fucoidan has limited solubility in alcohols.  
The relative stability of fucoidan fractions compared to conventionally produced antivenoms means 
that no cold storage would be required and a long shelf life could be anticipated. The development of 
fucoidan for this application could potentially limit the complications and distress caused by snakebite 
in a cost effective and realistic manner.  
7. Conclusions  
This review covers some of the more recent research into the bioactivity and discusses potential 
therapies from fucoidan. The research field has increased in the last decade and has started to produce 
clinical studies. This review has spanned potential applications as diverse as prion infection and 
osteoarthritis. The development of fucoidan fractions requires attention to the source and the required 
characteristics of the fraction, in addition to consideration of the route of delivery. Oral delivery 
appears promising, with research indicating therapeutic potential in different areas. Increasing Mar. Drugs 2011, 9  
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bioavailability is likely to be important for orally delivered fucoidan. Overall, the availability and 
safety of commercially available fucoidan preparations will lead to interesting adjunct and sole 
therapies for some neglected disease states in addition to providing new approaches to inflammation 
and fibrosis. 
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